Adult Dosing
Motion sickness; prevention
- PO 0.4-0.8 mg qid PRN; give first dose 1hr before travel
Parkinsonism
GI tract spasm
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- Monitor urinary function in men with BPH
- Caution advised in patients with cardiovascular disorders as it may cause tachycardia, hypertension, orthostatic hypotention
- Closely monitor patients with autonomic neuropathy
- Hypersensitivity reactions may develop in patients with a history of allergies or bronchial asthma
- Do not engage in activities requiring mental alertness, such as driving or operating dangerous machinery
- Monitor glaucoma therapy in patients with chronic open-angle glaucoma, adjust dose during use of scopolamine as mydriatic effect may increase intraocular pressure
- Prohibit use in children
- Rare idiosyncratic reactions have occurred even with ordinary therapeutic doses of scopolamine
- Bradycardia, hypotension, muscle weakness, equililbrium disturbance have occurred on discontinuing
- Reduction of bronchial secretions may lead to inspissation and formation of bronchial plugs in debilitated patients with chronic pulmonary disease
- Decreases tone and amplitude of contractions of the ureters and bladder
- CNS adverse effects have occurred
- Increased sensitivity to antimuscarinic effects have occurred
- Aggravates seizures and psychosis
- Interferes with the gastric secretion test
Use cautiously in:
- Renal impairment
- Hepatic impairment
- Cardiac disease
- Arrhythmias
- Pyloric obstruction
- Urinary bladder neck obstruction
- Intestinal obstruction
- GERD
- History of seizures
- History of psychosis
- Open angle glaucoma
- Co-administration of CNS depressants
- Co-administration of other anticholinergics
- Hyperthyroidism
- Pulmonary disease
- Autonomic neuropathy
- High environmental temperature
- Geriatrics
- Pediatrics
Supplemental Patient Information
- Caution patients about engaging in activities requiring mental alertness like driving a motor vehicle or operating dangerous machinery as drowsiness, disorientation and confusion may occur
Pregnancy Category:C
Breastfeeding: Safety unknown; information is unavailable on the use of scopolamine during breastfeeding. Prolong use of drug results in reduction of milk production or milk letdown. A single systemic or ophthalmic dose is unlikely to interfere with breastfeeding. On prolong use observe for signs of decreased lactation such as insatiety and poor weight gain. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. This drug is compatible and considered safe with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776/T6 last accessed 24 November 2010). Manufacturer advises caution while using in nursing women
